M&A Deal Summary |
|
---|---|
Date | 2021-12-28 |
Target | AiPharma Group |
Sector | Life Science |
Buyer(s) | Aditxt |
Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2017 |
Sector | Life Science |
Employees | 47 |
Revenue | 1M USD (2023) |
Aditxt is developing technologies focused on improving the immune system's health through immune monitoring and reprogramming. Aditxt was founded in 2017 and is based in Richmond, Virginia.
DEAL STATS | # |
---|---|
Overall | 1 of 4 |
Sector (Life Science) | 1 of 4 |
Type (Add-on Acquisition) | 1 of 3 |
State (Virginia) | 1 of 1 |
Country (United States) | 1 of 3 |
Year (2021) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2023-12-12 |
Evofem
San Diego, California, United States Evofem develops and anticipates commercializing innovative products that support and promote women as the primary healthcare consumers. It is currently identifying and developing new and novel products that specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections, and products that address or promote general health and wellbeing. Evofem is headquartered in San Diego, California. |
Buy | $100M |